U.S. market Closed. Opens in 7 hours 27 minutes

NMRA | Neumora Therapeutics, Inc. Common Stock Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-31
RevenueN/AN/AN/AN/A
Cost of Revenue668.00K2.70M1.55MN/A
Gross Profit-668.00K-2.70M-1.55MN/A
Operating Expenses187.53M135.87M237.32M95.52M
Selling, General & Admin44.81M31.12M24.55M8.39M
Research & Development142.72M104.75M212.78M87.13M
Other Operating Expenses63.90M405.00K11.00K-3.75M
Operating Income-188.19M-135.87M-237.32M-95.52M
Other Expenses / Income-47.46M405.00K11.00K-3.75M
Before Tax Income-235.66M-130.90M-237.31M-99.27M
Income Tax Expenses268.00K-4.56M301.44K-101.30K
Net Income-235.93M-130.90M-237.31M-99.27M
Interest ExpensesN/AN/AN/AN/A
Basic Shares Outstanding158.83M151.95M151.95M151.95M
Diluted Shares Outstanding158.83M151.95M151.95M151.95M
EBITDA-187.53M-135.28M-236.78M-95.41M
EBITDA Margin0.00%0.00%0.00%0.00%
EBIT-235.66M-135.47M-237.01M-99.37M
EBIT Margin0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙